Fibulin-3 is a novel TGF-β pathway inhibitor in the breast cancer microenvironment

Oncogene

Volumn 34, Issue 45, 2015, Pages 5635-5647

  Tian, H ^a   Liu, J ^a,b   Chen, J ^a   Gatza, M L ^c   Blobe, G C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b KUNMING INSTITUTE OF BOTANY   (China)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBULIN; FIBULIN 3; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; UNCLASSIFIED DRUG; EFEMP1 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SCLEROPROTEIN; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR; TUMOR PROTEIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; COMPLEX FORMATION; CONTROLLED STUDY; CORRELATIONAL STUDY; ENDOTHELIAL PERMEABILITY; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INVESTIGATIVE PROCEDURES; MOUSE; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SECRETION; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84947036280     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.13     Document Type: Article

References (50)

1. Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 2011; 121: 3804-3809
2. Culig Z. Cytokine disbalance in common human cancers. Biochim Biophys Acta 2011; 1813: 308-314
3. Hynes NE, Watson CJ. Mammary gland growth factors: roles in normal development and in cancer. Cold Spring Harb Perspect Biol 2010; 2: a003186
4. Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev 2006; 17: 325-337
5. Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res 2005; 11: 937s-943s
6. Moses H, Barcellos-Hoff MH. TGF-beta biology in mammary development and breast cancer. Cold Spring Harb Perspect Biol 2011; 3: a003277
7. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-1358
8. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 1992; 71: 1003-1014
9. Andres JL, DeFalcis D, Noda M, Massague J. Binding of two growth factor families to separate domains of the proteoglycan betaglycan. J Biol Chem 1992; 267: 5927-5930
10. Massague J. TGFbeta signaling: receptors, transducers, and Mad proteins. Cell 1996; 85: 947-950
11. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390: 465-471
12. ten Dijke P, Miyazono K, Heldin CH. Signaling inputs converge on nuclear effectors in TGF-beta signaling. Trends Biochem Sci 2000; 25: 64-70
13. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-beta responses. Cell 1998; 95: 737-740
14. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGFbeta family signalling. Nature 2003; 425: 577-584
15. Imamura T, Hikita A, Inoue Y. The roles of TGF-beta signaling in carcinogenesis and breast cancer metastasis. Breast Cancer 2012; 19: 118-124
16. Zu X, Zhang Q, Cao R, Liu J, Zhong J, Wen G, et al. Transforming growth factorbeta signaling in tumor initiation, progression and therapy in breast cancer: an update. Cell Tissue Res 2012; 347: 73-84
17. Drabsch Y, ten Dijke P. TGF-beta signaling in breast cancer cell invasion and bone metastasis. J Mammary Gland Biol Neoplasia 2011; 16: 97-108
18. Bierie B, Moses HL. Gain or loss of TGFbeta signaling in mammary carcinoma cells can promote metastasis. Cell Cycle 2009; 8: 3319-3327
19. Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res 2011; 13: 227
20. Mao Y, Keller ET, Garfield DH, Shen K, Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 2013; 32: 303-315
21. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004; 6: 17-32
22. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008; 27: 5904-5912
23. Buck MB, Knabbe C. TGF-beta signaling in breast cancer. Ann NY Acad Sci 2006; 1089: 119-126
24. Gold LI. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog 1999; 10: 303-360
25. Chang CF, Westbrook R, Ma J, Cao D. Transforming growth factor-beta signaling in breast cancer. Front Biosci 2007; 12: 4393-4401
26. Hanks BA, Holtzhausen A, Evans KS, Jamieson R, Gimpel P, Campbell OM, et al. Type III TGF-beta receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest 2013; 123: 3925-3940
27. Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, et al. The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest 2007; 117: 206-217
28. Lee JK, Park SR, Jung BK, Jeon YK, Lee YS, Kim MK, et al. Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PLoS ONE 2013; 8: e84256
29. O'Brien K, Rani S, Corcoran C, Wallace R, Hughes L, Friel AM, et al. Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. Eur J Cancer 2013; 49: 1845-1859
30. Cho JA, Park H, Lim EH, Lee KW. Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. Int J Oncol 2012; 40: 130-138
31. Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, Vonica A, et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 2012; 150: 764-779
32. Gallagher WM, Currid CA, Whelan LC. Fibulins and cancer: friend or foe?Trends Mol Med 2005; 11: 336-340
33. Argraves WS, Greene LM, Cooley MA, Gallagher WM. Fibulins: physiological and disease perspectives. EMBO Rep 2003; 4: 1127-1131
34. Kobayashi N, Kostka G, Garbe JH, Keene DR, Bachinger HP, Hanisch FG, et al. A comparative analysis of the fibulin protein family. Biochemical characterization, binding interactions, and tissue localization. J Biol Chem 2007; 282: 11805-11816
35. Luo R, Zhang M, Liu L, Lu S, Zhang CZ, Yun J. Decrease of fibulin-3 in hepatocellular carcinoma indicates poor prognosis. PLoS ONE 2013; 8: e70511
36. Sadr-Nabavi A, Ramser J, Volkmann J, Naehrig J, Wiesmann F, Betz B, et al. Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer 2009; 124: 1727-1735
37. Tong JD, Jiao NL, Wang YX, Zhang YW, Han F. Downregulation of fibulin-3 gene by promoter methylation in colorectal cancer predicts adverse prognosis. Neoplasma 2011; 58: 441-448
38. Kim YJ, Yoon HY, Kim SK, Kim YW, Kim EJ, Kim IY, et al. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res 2011; 17: 4523-4530
39. Camaj P, Seeliger H, Ischenko I, Krebs S, Blum H, De Toni EN, et al. EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells. Biol Chem 2009; 390: 1293-1302
40. Hwang CF, Chien CY, Huang SC, Yin YF, Huang CC, Fang FM, et al. Fibulin-3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity. J Pathol 2010; 222: 367-379
41. Hu B, Nandhu MS, Sim H, Agudelo-Garcia PA, Saldivar JC, Dolan CE, et al. Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling. Cancer Res 2012; 72: 3873-3885
42. Chen X, Meng J, Yue W, Yu J, Yang J, Yao Z, et al. Fibulin-3 suppresses Wnt/betacatenin signaling and lung cancer invasion. Carcinogenesis 2014; 35: 1707-1716
43. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998; 67: 753-791
44. ten Dijke P, Miyazono K, Heldin CH. Signaling via hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. Curr Opin Cell Biol 1996; 8: 139-145
45. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, et al. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 2003; 112: 1116-1124
46. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518-524
47. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential diss.e.m.ination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52: 1399-1405
48. Kim EJ, Lee SY, Woo MK, Choi SI, Kim TR, Kim MJ, et al. Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation. Int J Oncol 2012; 40: 402-408
49. Wang Z, Yuan X, Jiao N, Zhu H, Zhang Y, Tong J. CDH13 and FLBN3 gene methylation are associated with poor prognosis in colorectal cancer. Pathol Oncol Res 2012; 18: 263-270
50. Laib AM, Bartol A, Alajati A, Korff T, Weber H, Augustin HG. Spheroid-based human endothelial cell microvessel formation in vivo. Nat Protoc 2009; 4: 1202-1215